New insights into the immunopathology and control of dengue virus infection

Nature Reviews Immunology

Volumn 15, Issue 12, 2015, Pages 745-759

  Screaton, Gavin ^a   Mongkolsapaya, Juthathip ^a,b   Yacoub, Sophie ^c   Roberts, Catherine ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EPITOPE; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; CROSS REACTION; CRYOELECTRON MICROSCOPY; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; DRUG CONFORMATION; DRUG EFFICACY; HUMAN; IMMUNOPATHOLOGY; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; T LYMPHOCYTE; VACCINATION; VIRION; BIOLOGICAL MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIFE CYCLE STAGE; PHYSIOLOGY; VIROLOGY;

ANTIBODIES, MONOCLONAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIFE CYCLE STAGES; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 84948706705     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3916     Document Type: Review

References (152)

1. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
2. Simmons, C. P., Farrar, J. J., Nguyen v, V. & Wills, B. Dengue. N. Engl. J. Med. 366, 1423-1432 (2012).
3. Kuhn, R. J. et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725 (2002). This study shows the first structure of a mature flavivirus; the dengue virion is shown to consist of 90 E protein dimers arranged into a smooth virus particle.
4. Li, L. et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319, 1830-1834 (2008). This is an important study demonstrating the structure and linkage of the prM protein to the E protein.
5. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl Acad. Sci. USA 100, 6986-6991 (2003).
6. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319 (2004). This study shows how the structure of dengue E protein changes from dimer to trimer after membrane fusion.
7. Yu, I. M. et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319, 1834-1837 (2008).
8. Zhang, Y. et al. Structures of immature flavivirus particles. EMBO J. 22, 2604-2613 (2003). This study describes how the arrangement of prM protein and E protein leads to the formation of the spiky trimers on immature dengue virions.
9. Zhang, Y. et al. Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618 (2004).
10. Mukhopadhyay, S., Kuhn, R. J. & Rossmann, M. G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13-22 (2005).
11. Junjhon, J. et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 84, 8353-8358 (2010).
12. Dowd, K. A., Mukherjee, S., Kuhn, R. J. & Pierson, T. C. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J. Virol. 88, 11726-11737 (2014).
13. Cherrier, M. V. et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 28, 3269-3276 (2009).
14. Mukherjee, S. et al. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J. Virol. 88, 7210-7220 (2014).
15. Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748 (2010). This study reveals that there is a high proportion of prM-specific antibodies among human mAbs, and these antibodies do not effectively neutralize dengue virus but instead potently enhance the infection (that is, ADE).
16. Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170-177 (2015). This study describes mAbs directed against a previously unknown epitope, the EDE; these mAbs are broadly neutralizing across dengue serotypes.
17. Heinz, F. X. et al. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198, 109-117 (1994).
18. Rodenhuis-Zybert, I. A. et al. Immature dengue virus: a veiled pathogen? PLoS Pathog. 6, e1000718 (2010).
19. Plevka, P. et al. Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres. EMBO Rep. 12, 602-606 (2011).
20. Cruz-Oliveira, C. et al. Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol. Rev. 39, 155-170 (2015).
21. Halstead, S. B. et al. Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses. Yale J. Biol. Med. 42, 261-275 (1970).
22. Sangkawibha, N. et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120, 653-669 (1984).
23. Avirutnan, P. et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193, 1078-1088 (2006).
24. Libraty, D. H. et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185, 1213-1221 (2002).
25. Libraty, D. H. et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 186, 1165-1168 (2002).
26. Rothman, A. L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11, 532-543 (2011).
27. Nguyen, T. H. et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J. Infect. Dis. 189, 221-232 (2004).
28. Dejnirattisai, W. et al. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J. Immunol. 181, 5865-5874 (2008).
29. Green, S. et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J. Infect. Dis. 179, 755-762 (1999).
30. Bethell, D. B. et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J. Infect. Dis. 177, 778-782 (1998).
31. Ferrara, J. L., Abhyankar, S. & Gilliland, D. G. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 25, 1216-1217 (1993).
32. Ramachandran, G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence 5, 213-218 (2014).
33. de Jong, M. D. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203-1207 (2006).
34. Chen, Y. et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3, 866-871 (1997).
35. Avirutnan, P. et al. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog. 3, e183 (2007).
36. Avirutnan, P. et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 207, 793-806 (2010).
37. St John, A. L. Influence of mast cells on dengue protective immunity and immune pathology. PLoS Pathog. 9, e1003783 (2013).
38. Rothman, A. L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113, 946-951 (2004).
39. Duangchinda, T. et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl Acad. Sci. USA 107, 16922-16927 (2010).
40. Kurane, I., Zeng, L., Brinton, M. A. & Ennis, F. A. Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4. Virology 240, 169-174 (1998).
41. Livingston, P. G. et al. Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J. Immunol. 154, 1287-1295 (1995).
42. Mongkolsapaya, J. et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9, 921-927 (2003). This paper describes original antigenic sin in T cell responses to dengue virus infection.
43. Mongkolsapaya, J. et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 176, 3821-3829 (2006).
44. Weiskopf, D. et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl Acad. Sci. USA 110, E2046-E2053 (2013). This study shows that cross-reactive T cells from primary infection expand during secondary infection (original antigenic sin), but the overall quality of the responses is not compromised.
45. Yauch, L. E. et al. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182, 4865-4873 (2009). This study shows the protective role of CD8+ T cells in a mouse model of dengue virus infection.
46. Mathew, A., Townsley, E. & Ennis, F. A. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol. 9, 411-425 (2014).
47. Rivino, L. et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J. Virol. 87, 2693-2706 (2013).
48. Zompi, S., Santich, B. H., Beatty, P. R. & Harris, E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J. Immunol. 188, 404-416 (2012). This study demonstrates that both cross-reactive antibodies and T cells protect mice from secondary heterotypic dengue virus infection.
49. Mathew, A. et al. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1. 2a. J. Clin. Invest. 98, 1684-1691 (1996).
50. Mathew, A. et al. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J. Virol. 72, 3999-4004 (1998).
51. Green, S. et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J. Infect. Dis. 180, 1429-1435 (1999).
52. Zivna, I. et al. T cell responses to an HLA-B∗07-restricted epitope on the dengue NS3 protein correlate with disease severity. J. Immunol. 168, 5959-5965 (2002).
53. Dung, N. T. et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J. Immunol. 184, 7281-7287 (2010).
54. Friberg, H. et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci. Rep. 1, 51 (2011).
55. Rivino, L. et al. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sci. Transl. Med. 7, 278ra35 (2015). This study demonstrates that dengue virus-specific T cells migrate to peripheral tissues, such as the skin, during the acute phase of infection.
56. Kurane, I., Meager, A. & Ennis, F. A. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon γ production, and cytotoxic activity. J. Exp. Med. 170, 763-775 (1989).
57. Kurane, I., Brinton, M. A., Samson, A. L. & Ennis, F. A. Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J. Virol. 65, 1823-1828 (1991).
58. Fazekas de St, G. & Webster, R. G. Disquisitions of original antigenic sin. I. Evidence in man. J. Exp. Med. 124, 331-345 (1966).
59. Singh, R. A., Rodgers, J. R. & Barry, M. A. The role of T cell antagonism and original antigenic sin in genetic immunization. J. Immunol. 169, 6779-6786 (2002).
60. Weiskopf, D. et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl Acad. Sci. USA 112, E4256-E4263 (2015).
61. Coffey, L. L. et al. Human genetic determinants of dengue virus susceptibility. Microbes Infect. 11, 143-156 (2009).
62. Yauch, L. E. et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185, 5405-5416 (2010).
63. Zellweger, R. M. et al. CD8+ T cells can mediate short-term protection against heterotypic dengue reinfection in mice. J. Virol. 89, 6494-6505 (2015).
64. Halstead, S. B. Controversies in dengue pathogenesis. Paediatr. Int. Child Health 32, 5-9 (2012).
65. Guzman, M. G., Alvarez, M. & Halstead, S. B. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 158, 1445-1459 (2013).
66. Chan, K. R. et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc. Natl Acad. Sci. USA 111, 2722-2727 (2014).
67. Zompi, S. & Harris, E. Animal models of dengue virus infection. Viruses 4, 62-82 (2012).
68. Simmons, C. P. et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196, 416-424 (2007).
69. Halstead, S. B. et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8, 1474-1479 (2002).
70. Kliks, S. C., Nimmanitya, S., Nisalak, A. & Burke, D. S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38, 411-419 (1988). References 68 and 70 demonstrate that maternal antibodies contribute to the development of severe disease in infants experiencing primary dengue virus infection.
71. Pierson, T. C. Modeling antibody-enhanced dengue virus infection and disease in mice: protection or pathogenesis? Cell Host Microbe 7, 85-86 (2010).
72. Mohsin, S. N. et al. Association of FcγRIIa polymorphism with clinical outcome of dengue infection: first insight from Pakistan. Am. J. Trop. Med. Hyg. 93, 691-696 (2015).
73. Garcia, G. et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcγRIIa polymorphism. Am. J. Trop. Med. Hyg. 82, 1153-1156 (2010).
74. Loke, H. et al. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin D receptor and Fcγ receptor IIa genes. Am. J. Trop. Med. Hyg. 67, 102-106 (2002).
75. da Silva Voorham, J. M. et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS ONE 7, e29957 (2012).
76. Rodenhuis-Zybert, I. A. et al. A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J. Virol. 85, 11800-11808 (2011). This paper shows that immature dengue virions can be driven to become infectious through ADE.
77. Midgley, C. M. et al. An in-depth analysis of original antigenic sin in dengue virus infection. J. Virol. 85, 410-421 (2011).
78. Pierson, T. C. et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-145 (2007). This study measured the number of antibodies required for neutralization and enhancement of infection.
79. Guzman, M. G. et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg. Infect. Dis. 13, 282-286 (2007).
80. Sabin, A. B. Research on dengue during World War, II. Am. J. Trop. Med. Hyg. 1, 30-50 (1952).
81. Bhamarapravati, N. & Sutee, Y. Live attenuated tetravalent dengue vaccine. Vaccine 18 (Suppl. 2), 44-47 (2000).
82. Sun, W. et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin. 5, 33-40 (2009).
83. Edelman, R. et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69, 48-60 (2003).
84. Kanesa-thasan, N. et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179-3188 (2001).
85. Guy, B. et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29, 7229-7241 (2011).
86. Kirkpatrick, B. D. et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 212, 702-710 (2015).
87. Osorio, J. E. et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14, 830-838 (2014).
88. Watanaveeradej, V. et al. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am. J. Trop. Med. Hyg. 91, 119-128 (2014).
89. Villar, L. A. et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr. Infect. Dis. J. 32, 1102-1109 (2013).
90. Sabchareon, A. et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380, 1559-1567 (2012).
91. Lanata, C. F. et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 30, 5935-5941 (2012).
92. Leo, Y. S. et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum. Vaccin. Immunother. 8, 1259-1271 (2012).
93. Capeding, R. Z. et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29, 3863-3872 (2011).
94. Villar, L. et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372, 113-123 (2015).
95. Capeding, M. R. et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358-1365 (2014). References 94 and 95 describe the first ever Phase III trial of a dengue vaccine, which showed an overall efficacy of 64. 7% in children from Latin America and 56. 5% in Asian children, respectively.
96. Hadinegoro, S. R. et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195-1206 (2015). This study is a 3-year follow up of the CYD-TDV vaccine involving 35, 000 children; vaccine efficacy was higher in children over 9 years old compared with children younger than 9 years, and the younger age group was also associated with increased hospitalization.
97. Wu, S. F. et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21, 3919-3929 (2003).
98. Amorim, J. H. et al. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine 30, 837-845 (2012).
99. Bhoomiboonchoo, P. et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. BMC Publ. Health 15, 250 (2015).
100. Olkowski, S. et al. Reduced risk of disease during postsecondary dengue virus infections. J. Infect. Dis. 208, 1026-1033 (2013).
101. Gibbons, R. V. et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg. 77, 910-913 (2007).
102. Guy, B. et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80, 302-311 (2009).
103. Dayan, G. H. et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum. Vaccin. Immunother. 10, 2853-2863 (2014).
104. Durbin, A. P. et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J. Infect. Dis. 207, 957-965 (2013).
105. George, S. L. et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded Phase 1 clinical trial. J. Infect. Dis. 212, 1032-1041 (2015).
106. Thomas, S. J. & Rothman, A. L. Trials and tribulations on the path to developing a dengue vaccine. Vaccine http://dx. doi. org/10. 1016/j. vaccine. 2015. 05. 095 (2015). This is a comprehensive review on dengue vaccine development.
107. Brien, J. D. et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84, 10630-10643 (2010).
108. Crill, W. D. & Roehrig, J. T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75, 7769-7773 (2001).
109. Gromowski, G. D. & Barrett, A. D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366, 349-360 (2007)
110. Gromowski, G. D., Barrett, N. D. & Barrett, A. D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82, 8828-8837 (2008).
111. Roehrig, J. T., Bolin, R. A. & Kelly, R. G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317-328 (1998).
112. Shrestha, B. et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6, e1000823 (2010).
113. Sukupolvi-Petty, S. et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84, 9227-9239 (2010). This is one of several studies from this group defining the epitopes that are recognized by protective antibodies and showing that the viral strains and/or genotypes have an influence on neutralizing potency.
114. Sukupolvi-Petty, S. et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81, 12816-12826 (2007).
115. Sukupolvi-Petty, S. et al. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J. Virol. 87, 8826-8842 (2013).
116. Wahala, W. M. et al. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 6, e1000821 (2010).
117. Oliphant, T. et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80, 12149-12159 (2006).
118. Lai, C. -Y. et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82, 6631-6643 (2008).
119. Oliphant, T. et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81, 11828-11839 (2007).
120. Crill, W. D., Hughes, H. R., Delorey, M. J. & Chang, G. J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4, e4991 (2009).
121. Smith, S. A. et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4, e00873-00813 (2013). This paper shows the characterization of a panel of human mAbs and the identification of an antibody that recognizes all four dengue virus serotypes with potent neutralizing activity. The epitope of this mAb was shown to be on the BC loop of a monomeric E protein.
122. Robinson, L. N. et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell 162, 493-504 (2015).
123. Oliphant, T. et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11, 522-530 (2005).
124. Lok, S. M. et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15, 312-317 (2008). This interesting paper describes the crystal structure of the mAb 1A1D2 binding to the viral E protein, which reorganizes to expose hidden epitopes, suggesting that the virus can breathe to accommodate antibody binding.
125. Williams, K. L., Wahala, W. M., Orozco, S., de Silva, A. M. & Harris, E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429, 12-20 (2012).
126. Midgley, C. M. et al. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J. Immunol. 188, 4971-4979 (2012).
127. Dowd, K. A., Jost, C. A., Durbin, A. P., Whitehead, S. S. & Pierson, T. C. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7, e1002111 (2011).
128. Fibriansah, G. et al. Structural changes in dengue virus when exposed to a temperature of 37°C. J. Virol. 87, 7585-7592 (2013).
129. Zhang, X. et al. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl Acad. Sci. USA 110, 6795-6799 (2013).
130. Fibriansah, G. et al. Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349, 88-91 (2015).
131. Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871-875 (2004).
132. Yu, X., McGraw, P. A., House, F. S. & Crowe, J. E. Jr. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. J. Immunol. Methods 336, 142-151 (2008).
133. Smith, K. et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372-384 (2009).
134. Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271-283 (2010).
135. de Alwis, R. et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop. Dis. 5, e1188 (2011).
136. Smith, S. A. et al. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J. Virol. 86, 2665-2675 (2012).
137. Smith, S. A. et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207, 1898-1908 (2013).
138. Oceguera, L. F. et al. Flavivirus serology by western blot analysis. Am. J. Trop. Med. Hyg. 77, 159-163 (2007).
139. Teoh, E. P. et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4, 139ra83 (2012).
140. Fibriansah, G. et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 6, 358-371 (2014).
141. Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109-113 (2015).
142. Kaufmann, B. et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl Acad. Sci. 107, 18950-18955 (2010).
143. Fibriansah, G. et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun. 6, 6341 (2015). References 130, 139, 140 and 143 are EM studies that show the binding of potent dengue virus serotype-specific antibodies recognizing conformation-dependent epitopes. All but one recognize epitopes across three E protein monomers of the two adjacent dimers on the viral particle.
144. McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
145. McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013).
146. Yacoub, S., Wertheim, H., Simmons, C. P., Screaton, G. & Wills, B. Cardiovascular manifestations of the emerging dengue pandemic. Nat. Rev. Cardiol. 11, 335-345 (2014).
147. Trung, D. T. et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop. Dis. 6, e1679 (2012).
148. Whitehorn, J. et al. Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl Trop. Dis. 8, e3025 (2014).
149. Mackenzie, J. S., Gubler, D. J. & Petersen, L. R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98-S109 (2004).
150. Williams, K. L. et al. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog. 9, e1003157 (2013).
151. Smith, S. A. et al. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol. 88, 12233-12241 (2014).
152. de Alwis, R. et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA 109, 7439-7444 (2012).